Document is current
Any future updates will be listed below
-
Authors
Ghofrani, Hossein-Ardeschir http://orcid.org/0000-0002-2029-4419
Gomberg-Maitland, Mardi
Zhao, Lan
Grimminger, Friedrich http://orcid.org/0000-0001-8725-6276
- License Information
-
More Information
Article History
Accepted: 4 July 2024
First Online: 7 August 2024
Competing interests
: H.-A.G. has received fees for lectures and/or consultations from Aerovate, Altavant/Enzyvant, Bayer AG, Gossamer Bio, Janssen/Actelion, MorphogenIX, MSD/Acceleron, Pfizer, and United Therapeutics and fees for participation in a data safety monitoring board from Insmed. His spouse was an employee of Altavant/Enzyvant from January 2023 until August 2023; her work for the company was intentionally separated from H.-A.G.’s active interactions in conjunction with the clinical development programme. M.G.-M. has received research grants paid to her institution from Aerovate, Altavant, Acceleron (a subsidiary of Merck), and Bayer and consultation fees from Aerami, Acceleron (a subsidiary of Merck), Bayer, Janssen Biotech, Keros Therapeutics, and United Therapeutics Corporation. She holds leadership roles on the Board of Directors for the International Society of Heart and Lung Transplantation and the Scientific Advisory Board of United Therapeutics. Her spouse is a Senior Director in Clinical Development at Intellia Therapeutics. The other authors declare no competing interests.
